Cancer-targeted, virus-encoded, regulatable t (catvert) or nk cell (catvern) linkers

A technology that encodes, immune effector cells in the field of cancer-targeted, virus-encoded, regulated T-cell (CATVERT) or NK-cell (CATVERN) linkers to address side effects, gene inactivation, etc.

Pending Publication Date: 2021-11-12
RES INST AT NATIONWIDE CHILDRENS HOSPITAL
View PDF29 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Another application is where gene therapy may cause unwanted side effects and it is desired to inactivate the gene

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cancer-targeted, virus-encoded, regulatable t (catvert) or nk cell (catvern) linkers
  • Cancer-targeted, virus-encoded, regulatable t (catvert) or nk cell (catvern) linkers
  • Cancer-targeted, virus-encoded, regulatable t (catvert) or nk cell (catvern) linkers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0497] Example 1 - Generation of CD3xGD2-HDD Dimert Using Exemplary CD3xGD2-HDD TransJoin

[0498] Map of exemplary AAV constructs used to test CD3xGD2-HDD expression.

[0499] As a proof of principle, a previously described bispecific molecule targeting human CD3 on T cells and the disialoganglioside GD2 on neuroblastoma and other types of cancer cells was expressed. This bispecific protein has the amino acid sequences of the heavy and light chain variable regions of human CD3 derived from clone OKT3 (using a single-chain variable fragment format scFv), fused via a short linker (L) to the scFv construct against GD2 of 5F11 linked as a dimer via the HNF1a dimerization domain (HDD) as in Ahmed et al ., OncoImmunology , 4:4, e989776, DOI: 10.4161 / 2162402X.2014.989776 as reported. The vectorbuilder.com codon optimization tool (http: / / en.vectorbuilder.com / tool / codon-optimization.html) was used to reverse engineer the optimal human DNA coding sequence for CD3xGD2-HDD. The res...

Embodiment 2

[0523] Example 2 - Generation of CD19xCD3 Dimert using an exemplary CD19xCD3 TransJoin

[0524] Map of exemplary AAV constructs used to test CD19xCD3 Dimert expression.

[0525] The FDA-approved protein therapeutic, called blinatumomab, is a so-called bispecific T-cell engager (BiTE) that targets human CD19 and Human CD3 on T cells. Using the publicly available amino acid sequence of blinatumomab (http: / / www.drugbank.ca / drugs / DB09052) and further using the vectorbuilder.com codon optimization tool (http: / / en.vectorbuilder.com / tool / codon-optimization. html) to reverse engineer the optimal human DNA coding sequence for CD19xCD3. The resulting DNA sequence starting with the ATG start codon was synthesized and cloned into an adeno-associated virus expression cassette downstream of the chicken-actin-b-globin promoter (CAGp) with inverted terminal repeats derived from AAV2 sequence. Based on the discovery that alanine enhances secretion of proteins (Güler-Gane et al ., PLoS ...

Embodiment 3

[0555] Example 3 - Using OncoSkip and TransSkip to Simultaneously Target Oncogene Expression and Activate Therapeutic Transgene Expression

[0556] An overview of OncoSkip and TransSkip described in this article.

[0557] OncoSkip is an antisense morpholino that induces exon skipping in oncogenes. In some embodiments, OncoSkip is designed as an antisense morpholino that induces in oncogenes ( Figure 30 Left side of ) Exon skipping of key exons. For a proof-of-principle, KRAS (exons 1, 2, 3, by Figure 30 black-gold-gray on the left) and tested the morpholino group designed to skip KRAS exon 2 ( Figure 30 , shown as light gray bars on top of oncogenes), which contain the ATG initiation site, so normal expression of the oncogene is reduced. Derivatives of the same exons to be skipped were then created, but mutated to include multiple stop codons in each reading frame as well as flanking intronic sequences. A new intron-exon (STOP)-intron is then inserted into the transgen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

Recombinant polynucleotides and vectors containing an engineered (artificial) exon-intron-exon gene structure in a transgene are provided, which undergoes splicing when it is expressed in a target cell.

Description

[0001] Statement of Government Support [0002] This invention was made with government support under NF170075 awarded by the Department of Defense. The government has certain rights in this invention. [0003] Cross References to Related Applications [0004] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62 / 808264, filed February 20, 2019, the contents of which are incorporated herein by reference in their entirety. Background technique [0005] Gene transfer as a treatment for disease (ie, gene therapy) is now a reality. In 2017, the FDA approved Luxturna, an adeno-associated virus (AAV) engineered to stably express a normal copy of the RPE65 gene in retinal cells, for the treatment of congenital retinal dystrophies. In 2019, the FDA approved Zolgensma, an AAV designed to express SMN1 in motor neurons to treat spinal muscular atrophy. Ongoing clinical trials using AAV vectors to replace gene function in other diseases have ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C12N15/86C12N15/864C12N15/113
CPCC12N15/113C12N15/86C12N2310/11C12N2320/33C12N2320/31C12N2310/3233C12N15/1135C12N2750/14143C07K2317/622C07K16/2809C07K16/3084C07K2317/31C07K16/468C07K16/28C12N15/864C12N5/0636C12N5/0646A61P35/00A61K48/00C12N2510/00A61K2039/505A61K31/7105A61K39/39558A61K48/005A61K2039/5258C07K16/32C07K2319/00C12N15/1138C12N15/62C12N2710/16033
Inventor 蒂莫西·P·克里普陈淳宇布莱恩·胡特泽恩马克·柯里尔王品怡道恩·钱德勒
Owner RES INST AT NATIONWIDE CHILDRENS HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap